Macrophage activation syndrome in a patient with axial spondyloarthritis on adalimumab

Macrophage activation syndrome (MAS) is a rare and potentially fatal condition characterized by excessive activation and uncontrolled proliferation of T lymphocytes and macrophages, leading to overwhelming systemic inflammation and cytokine release. MAS has been reported with viral infections, autoi...

Descripción completa

Detalles Bibliográficos
Autores principales: Baker, Rahaf, Liew, Jean W., Simonson, Paul D., Soma, Lori A., Starkebaum, Gordon
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer London 2018
Materias:
Case Based Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7087649/
https://www.ncbi.nlm.nih.gov/pubmed/30535729
http://dx.doi.org/10.1007/s10067-018-4387-5
_version_ 1783509374656839680
author Baker, Rahaf
Liew, Jean W.
Simonson, Paul D.
Soma, Lori A.
Starkebaum, Gordon
author_facet Baker, Rahaf
Liew, Jean W.
Simonson, Paul D.
Soma, Lori A.
Starkebaum, Gordon
author_sort Baker, Rahaf
collection PubMed
description Macrophage activation syndrome (MAS) is a rare and potentially fatal condition characterized by excessive activation and uncontrolled proliferation of T lymphocytes and macrophages, leading to overwhelming systemic inflammation and cytokine release. MAS has been reported with viral infections, autoimmune disorders, malignancies, and medications. We describe a case of a patient with axial spondyloarthritis (axSpA) treated with adalimumab, who presented with MAS.
format Online
Article
Text
id pubmed-7087649
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Springer London
record_format MEDLINE/PubMed
spelling pubmed-70876492020-03-23 Macrophage activation syndrome in a patient with axial spondyloarthritis on adalimumab Baker, Rahaf Liew, Jean W. Simonson, Paul D. Soma, Lori A. Starkebaum, Gordon Clin Rheumatol Case Based Review Macrophage activation syndrome (MAS) is a rare and potentially fatal condition characterized by excessive activation and uncontrolled proliferation of T lymphocytes and macrophages, leading to overwhelming systemic inflammation and cytokine release. MAS has been reported with viral infections, autoimmune disorders, malignancies, and medications. We describe a case of a patient with axial spondyloarthritis (axSpA) treated with adalimumab, who presented with MAS. Springer London 2018-12-07 2019 /pmc/articles/PMC7087649/ /pubmed/30535729 http://dx.doi.org/10.1007/s10067-018-4387-5 Text en © International League of Associations for Rheumatology (ILAR) 2018 This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic.
spellingShingle Case Based Review
Baker, Rahaf
Liew, Jean W.
Simonson, Paul D.
Soma, Lori A.
Starkebaum, Gordon
Macrophage activation syndrome in a patient with axial spondyloarthritis on adalimumab
title Macrophage activation syndrome in a patient with axial spondyloarthritis on adalimumab
title_full Macrophage activation syndrome in a patient with axial spondyloarthritis on adalimumab
title_fullStr Macrophage activation syndrome in a patient with axial spondyloarthritis on adalimumab
title_full_unstemmed Macrophage activation syndrome in a patient with axial spondyloarthritis on adalimumab
title_short Macrophage activation syndrome in a patient with axial spondyloarthritis on adalimumab
title_sort macrophage activation syndrome in a patient with axial spondyloarthritis on adalimumab
topic Case Based Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7087649/
https://www.ncbi.nlm.nih.gov/pubmed/30535729
http://dx.doi.org/10.1007/s10067-018-4387-5
work_keys_str_mv AT bakerrahaf macrophageactivationsyndromeinapatientwithaxialspondyloarthritisonadalimumab
AT liewjeanw macrophageactivationsyndromeinapatientwithaxialspondyloarthritisonadalimumab
AT simonsonpauld macrophageactivationsyndromeinapatientwithaxialspondyloarthritisonadalimumab
AT somaloria macrophageactivationsyndromeinapatientwithaxialspondyloarthritisonadalimumab
AT starkebaumgordon macrophageactivationsyndromeinapatientwithaxialspondyloarthritisonadalimumab

Ejemplares similares